AN

Ananda Pharma Plc

Develops approved cannabinoid medicines for pain, epilepsy, and heart failure.

ANAN | Aquis Stock Exchange

Overview

Corporate Details

ISIN(s):
GB00BDQPXQ60
LEI:
894500DFM8VOC5FW4X47
Country:
United Kingdom
Address:
6th Floor, 60 Gracechurch Street, EC3V 0HR London
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Ananda Pharma Plc is a biopharmaceutical company focused on developing and commercializing regulatory-approved medicines derived from cannabinoids. The company targets complex conditions with significant unmet medical needs, primarily focusing on chronic inflammatory pain (including chemotherapy-induced peripheral neuropathy and endometriosis), drug-resistant epilepsies, and heart failure with preserved ejection fraction (HFpEF). Its integrated approach spans research, drug candidate development, clinical trials conducted with research partners, and navigating regulatory pathways for marketing authorization. Ananda Pharma leverages the well-understood safety profile of cannabinoids to potentially accelerate its clinical development programs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-10 08:20
Regulatory News Service
Confirmation of receipt of £168k R&D tax refund
English 23.0 KB
2025-10-13 15:45
Interim Report
Interims for the six months ended 31 July 2025
English 129.3 KB
2025-09-26 12:10
Legal Proceedings Report
Ananda ends UCL/GOSH trials, prioritises MRX1
English 22.6 KB
2025-09-16 08:00
Regulatory News Service
Ananda attending Cannabinoid Summit
English 22.1 KB
2025-08-26 15:43
Post-Annual General Meeting Information
Result of Annual General Meeting
English 29.6 KB
2025-08-19 08:00
Report Publication Announcement
Webinar Presentation Release
English 21.3 KB
2025-07-30 14:49
Pre-Annual General Meeting Information
Notice of Annual General Meeting
English 21.8 KB
2025-07-30 13:44
Report Publication Announcement
Publication of Annual Report
English 44.2 KB
2025-06-23 08:00
Regulatory News Service
Key Milestone in MRX1 Path to Clinical Trials
English 23.3 KB

Automate Your Workflow. Get a real-time feed of all Ananda Pharma Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ananda Pharma Plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ananda Pharma Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Upstream Bio, Inc. Logo
Developing a monoclonal antibody for severe inflammatory and respiratory diseases.
United States of America
UPB
UroGen Pharma Ltd. Logo
Develops non-surgical therapies for urological cancers using proprietary hydrogel technology.
United States of America
URGN
Valbiotis Logo
Develops clinically tested, plant-based supplements for metabolic & cardiovascular health.
France
ALVAL
Valneva SE Logo
Develops and commercializes vaccines for infectious diseases like chikungunya, Lyme, and Zika.
France
VLA
Vanda Pharmaceuticals Inc. Logo
Develops and commercializes innovative therapies for central nervous system disorders.
United States of America
VNDA
Vaxcell-Bio Therapeutics Logo
Develops CAR-T and CAR-NK immunotherapies for solid tumors and canine lymphoma.
South Korea
323990
Vaxcyte, Inc. Logo
A clinical-stage company developing broad-spectrum vaccines for bacterial infectious diseases.
United States of America
PCVX
VENTURE LIFE GROUP PLC Logo
Develops, manufactures, and distributes consumer self-care products and medical devices globally.
United Kingdom
VLG
Ventyx Biosciences, Inc. Logo
Clinical-stage biopharma developing oral therapies for autoimmune, inflammatory & neuro diseases.
United States of America
VTYX
Verastem, Inc. Logo
Develops cancer medicines targeting the RAS/MAPK pathway, with an approved therapy for ovarian cancer.
United States of America
VSTM

Talk to a Data Expert

Have a question? We'll get back to you promptly.